Annual Financial Report
02/05/2023 07:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230502:nRSB9746Xa&default-theme=true RNS Number : 9746X RTW Venture Fund Limited 02 May 2023 LEI: 549300Q7EXQQH6KF7Z84 2 May 2023 RTW Venture Fund Limited Annual Financial Report Year ended 31 December 2022 A tagged copy of the above document was submitted to the National Storage Mechanism on 28 April 2023 and is available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism (https://data.fca.org.uk/#/nsm/nationalstoragemechanism) For Further Information: RTW Investments, LP +44 (0)20 7959 6361 Woody Stileman, Managing Director Krisha McCune, Director, Client Service Buchanan +44 (0)20 7466 5107 Charles Ryland Henry Wilson George Beale Numis +44 (0)20 7260 1000 Freddie Barnfield Nathan Brown Euan Brown BofA Securities +44 (0) 20 7628 1000 Edward Peel Kieran Millar About RTW Venture Fund Limited: RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies. Visit the RTW website at www.rtwfunds.com (https://protect.mimecast-offshore.com/s/eY8OCgLEp4SlY4JEFN_vEF) for more information. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END ACSSSDFFFEDSEII